

‘Management of acute-on-chronic liver failure’

MICROB-PREDICT and DECISION – Symposium

on 2nd July 2020, in Frankfurt, Germany

at the occasion of the EASL School of Hepatology on 3rd and 4th July 2020

Organizing committee:

Dr. Minneke Coenraad, gastroenterologist-hepatologist Leiden University Medical Center, The Netherlands, dissemination manager MICROB-PREDICT

Dr. Ameli Schwalber, concentris research management, Germany, project management office

Prof. Dr. Pierre-Emmanuel Rautou, professor of Hepatology Hôpital Beaujon, Inserm UMR, France, principal investigator DECISION, EF Clif, Barcelona, Spain

Prof. Dr. Jonel Trebicka, professor of Hepatology Goethe University Frankfurt, Germany, principal investigator MICROB-PREDICT, EF Clif, Barcelona, Spain

We would like to invite you for the MICROB-PREDICT and DECISION symposium, which will take place at July 2nd 2020 in Frankfurt, Germany, in the afternoon before the EASL School of Hepatology ‘Management of acute-on-chronic liver failure’.

At this symposium, several experts of both project consortia will present recent advances in the field of microbiome, introduce the role of proteomics and metabolomics in hepatology and discuss treatment strategies and their mechanisms of action in acute-on-chronic liver failure.

The gut microbiome, the gut barrier, microbial translocation and systemic inflammation have been identified as triggers for the development of decompensation and progression of decompensated cirrhosis to acute on chronic liver failure. Nowadays, we have access to high-end multiomics techniques, which allow us to develop tools for better stratification of patients with cirrhosis at risk of decompensation or acute on chronic liver failure and to develop personalized treatment strategies.

This symposium is aimed at young fellows enrolled in hepatology-oriented departments, more experienced clinicians who want to be exposed to the newest trends in hepatology and young researchers involved in microbiome and cirrhosis research.

Be aware that this symposium is connected to, but not part of the EASL School of Hepatology. This implies that there is no selection process for attendees of this symposium. The symposium is open to attendees of the EASL School and all other interested people. The symposium is free of cost. The number of attendees is limited to 40, so register soon!

We hope to welcome you in Frankfurt at July 2nd!

On behalf of the organizing committee,

Minneke Coenraad

Programme:

Chairs: M. Coenraad, J. Trebicka, PE Rautou

12:00 Registration and welcome coffee

12:30-13:00	ACLF and microbiome – introduction of the MICROB-PREDICT project (Jonel Trebicka, Goethe University Frankfurt, Germany; EF Clif Spain)
13:00-13:30	ACLF and combinatorial therapies – introduction of the DECISION project (Pierre-Emmanuel Rautou, Hôpital Beaujon, Inserm UMR, France)
13:30-14:00	Microbiome: recent insights and future challenges (Thea van Rossum, European Molecular Biology Laboratory, Germany)
14:00-14:30	Proteome and liver disease: how deep is deep enough (Lili Niu, Clinical Proteomics, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen)

14:30-15:00 Break

15:00-15:30	Metabolomics and its way into the hepatology (Christophe Junot, Commissariat a l'énergie atomique et aux énergies alternatives, France)
15:30-16:00	Mechanisms of action of albumin in cirrhosis (Joan Claria, Hospital Clinic -EFClif, Spain)
16:00-16:30	Role of albumin in treatment of cirrhosis (Minneke Coenraad, Leiden University Medical Center, The Netherlands)

www.microb-predict.eu

Contact

Prof. Dr. Jonel Trebicka

MICROB-PREDICT

Project coordinator

jonel.trebicka@efclif.com

+34 (0) 932 271 411

Mrs. Margaret Walker

EASL EU Public Affairs Consultant

margaret.walker@easloffice.eu

+44 (0) 774 712 117 5

Dr. Minneke Coenraad

MICROB-PREDICT

Dissemination manager

m.j.coenraad@lumc.nl

+31 (0) 611 371 146

Funding

MICROB-PREDICT and DECISION receive funding from the *European Union's Horizon 2020 research and innovation programme* under grant agreements No. 825694 and 847949. This reflects only the view of the authors, and the *European Commission* is not responsible for any use that may be made of the information it contains. Reproduction is authorised provided the source is acknowledged.

